COSTA MESA, Calif., July 10, 2018 ( – Uprise Health (formerly IBH Solutions), today announced the acquisition of Inflexxion, Inc. (“Inflexxion” or the “Company”), a healthcare data and analytics company that specializes in the collection, surveillance, monitoring and analysis of critical public health issues including prescription drug abuse, substance use, behavioral health, and pain management.

Based in Waltham, MA, and founded in 1989, Inflexxion provides proprietary behavioral health and pain-related assessment tools and data to national behavioral health and addiction treatment organizations, chronic pain clinics, health systems and regulatory authorities. Inflexxion’s data analytics division includes the National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO) to better understand prescription opioid and stimulant use and the effectiveness of abuse-deterrent formulations (ADF). Inflexxion’s clinical assessment and analytics tools include Addiction Severity Index (ASI), Behavioral Health Index (BHI), Comprehensive Health Assessment for Teens (CHAT), Screener and Opioid Assessment for Patients with Pain (SOAPP), Current Opioid Misuse Measure (COMM), Pain and Functioning Index (PFI) – that are designed to enhance quality of care and patient outcomes by targeting treatment plans based on severity of risk factors.

Dr. Ed Bosanac, CEO of Uprise Health said, “We are thrilled to welcome Inflexxion to the Uprise Health family. Their evidence-based clinical assessment tools will uniquely differentiate our population health management capabilities within our addiction severity, pain management, and risk evaluation offerings. As physical and behavioral health integration becomes increasingly more important, Inflexxion’s tools will enable our skilled clinicians to make data-informed treatment planning decisions for the 7+ million members we cover. In addition, Inflexxion’s leadership in the industry and innovative technology platform will significantly advance our opioid case management and workflow products for the disability and workers compensation insurance markets.”

“Becoming part of Uprise Health is an exciting new chapter for Inflexxion’s customers, products and team,” added Bruno Lempernesse, CEO of Inflexxion. “With such a large patient population and deep clinical roots, Uprise Health is a perfect strategic partner for Inflexxion, to quickly scale the distribution channel and enhance the effectiveness of our assessment tools. We look forward to working closely with the Uprise Health team to continue expanding our library of critical assessment tools to address the specific needs of our customers.”

About Integrated Behavioral Health, Inc.

Uprise Health is a pioneer in managed behavioral health and integrated employee assistance programs and services. As a boutique managed care company with a national footprint, Uprise Health partners with employers and health plans to provide clients personalized and customized behavioral health plans with high-quality clinical care, uncompromising service to patients, providers and clients with outcomes driven, cost-effective care plans. Along with its subsidiaries Reliant Behavioral Health (“RBH”), Quality Health Solutions (“QHS”), American Behavioral Health Benefit Managers (“ABBM”) and CFR EAP Preferred (“CFR”), Uprise Health has successfully managed treatment and benefits for self‐insured employers, medical and disability carriers, and health plans for over 30 years. Uprise Health currently serves over 7 Million members, representing 26,000 individual clients across the United States. Uprise Health strives to achieve and maintain a healthy, safe and productive pool of employees and members for employers and health plans. For more information, please visit

About Inflexxion, Inc.

Inflexxion, Inc. is a healthcare data and analytics company that has built a database of highly addictive prescription drug use and behaviors over nearly 30 years. Inflexxion works with healthcare organizations, medical professionals, pharmaceutical companies, and regulatory authorities to assess, track and improve patient care and inform public policy. Inflexxion collects, analyzes and disseminates extensive behavior and health-related data for pharmaceutical post-market surveillance, risk management, epidemiological studies, product improvements, abuse prevention and outcome measurement. Inflexxion’s unique data collection technology and processes include multiple data streams at the point-of-care, Internet monitoring, and web-surveys with hard to reach and at-risk populations. Inflexxion then combines this data with rigorous science and extensive clinical expertise, to assess patients, analyze behaviors, and develop intervention programs to reduce health-related risks, enhance clinical outcomes, and positively influence quality of care for prescription drug use and treatments.